Pub Date : 2025-02-10DOI: 10.1016/j.ad.2025.02.010
M E Gatica-Ortega, B Sánchez-Albisua, D M Arranz-Sánchez, B Pérez-Tato, A Sánchez-Gilo, S Córdoba-Guijarro, F J Ortiz-Frutos, N Hernández-Cano, E Gómez de la Fuente, M Elosua-González, M Bergón-Sendín, C García-Martín, T Sanz-Sánchez, O Mazuela-Díez, R Torres-Aranda, L Vergara-de-la-Campa, S Marinero-Escobedo, A Alegre-Bailo, A Garrido-Ríos, F Tous-Romero, J M Busto-Leis, C Sarró-Fuente, F J Rodríguez-Cuadrado, P García-Piqueras, P Beneyto, M A Pastor-Nieto
Background and objective: Vibratory urticaria/angioedema is confirmed by the vortex provocation test. It has been agreed to measure the perimeter of the forearm after exposure to the vortex to define a positive response to it.
Material and method: We evaluated the frequency of prior symptoms following vibratory stimuli in volunteers (using a questionnaire); the response to the vortex test in the same volunteers (increase in forearm perimeter, erythema, localized edema, heat, and pruritus); inter-rater reliability; and, the correlation between the questionnaire score and the response to the test.
Results: 140 volunteers participated. 17 were excluded due to dermographism. Of 123 without dermographism, 59% responded affirmatively to ≥1 item of the questionnaire. Localized erythema, heat or localized edema were observed in 58.5%; 38.2%; and 32.5%, respectively. 73,6% presented with itch. Mean intensity of itch was 3.44 95% CI (2.94-3.94). Interrater agreement was low regarding the increase in forearm circumference at three levels (intraclass correlation coefficient: 0.477 95% CI: 0.253-0.634; 0.496 95% CI: 0.280-0.647; and 0.370 95% CI: 0.100-0.559, respectively); and, optimal regarding erythema, heat and localized edema (Kappa index: 0.868; .756; and .757, respectively). A significant correlation was identified between the questionnaire score and the altered response to the test in its different variables.
Conclusions: We propose the variables: erythema; localized edema; heat; and, the intensity/speed of onset/duration of pruritus, to define a positive response to the vortex test given their ease of execution and the optimal inter-observer agreement.
{"title":"[[Translated article]]Erythema, Localized Edema and Heat vs Forearm Perimeter Increase. Time to Revise the Consensus Recommendations on the Vortex Provocation Test in Vibratory Urticaria-Angioedema?","authors":"M E Gatica-Ortega, B Sánchez-Albisua, D M Arranz-Sánchez, B Pérez-Tato, A Sánchez-Gilo, S Córdoba-Guijarro, F J Ortiz-Frutos, N Hernández-Cano, E Gómez de la Fuente, M Elosua-González, M Bergón-Sendín, C García-Martín, T Sanz-Sánchez, O Mazuela-Díez, R Torres-Aranda, L Vergara-de-la-Campa, S Marinero-Escobedo, A Alegre-Bailo, A Garrido-Ríos, F Tous-Romero, J M Busto-Leis, C Sarró-Fuente, F J Rodríguez-Cuadrado, P García-Piqueras, P Beneyto, M A Pastor-Nieto","doi":"10.1016/j.ad.2025.02.010","DOIUrl":"https://doi.org/10.1016/j.ad.2025.02.010","url":null,"abstract":"<p><strong>Background and objective: </strong>Vibratory urticaria/angioedema is confirmed by the vortex provocation test. It has been agreed to measure the perimeter of the forearm after exposure to the vortex to define a positive response to it.</p><p><strong>Material and method: </strong>We evaluated the frequency of prior symptoms following vibratory stimuli in volunteers (using a questionnaire); the response to the vortex test in the same volunteers (increase in forearm perimeter, erythema, localized edema, heat, and pruritus); inter-rater reliability; and, the correlation between the questionnaire score and the response to the test.</p><p><strong>Results: </strong>140 volunteers participated. 17 were excluded due to dermographism. Of 123 without dermographism, 59% responded affirmatively to ≥1 item of the questionnaire. Localized erythema, heat or localized edema were observed in 58.5%; 38.2%; and 32.5%, respectively. 73,6% presented with itch. Mean intensity of itch was 3.44 95% CI (2.94-3.94). Interrater agreement was low regarding the increase in forearm circumference at three levels (intraclass correlation coefficient: 0.477 95% CI: 0.253-0.634; 0.496 95% CI: 0.280-0.647; and 0.370 95% CI: 0.100-0.559, respectively); and, optimal regarding erythema, heat and localized edema (Kappa index: 0.868; .756; and .757, respectively). A significant correlation was identified between the questionnaire score and the altered response to the test in its different variables.</p><p><strong>Conclusions: </strong>We propose the variables: erythema; localized edema; heat; and, the intensity/speed of onset/duration of pruritus, to define a positive response to the vortex test given their ease of execution and the optimal inter-observer agreement.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-10DOI: 10.1016/j.ad.2025.02.008
C Pindado-Ortega, R Pirmez, D F Melo, L J F Binato, M L Porriño-Bustamante, J B Carpi, R Gil-Redondo, Á Hermosa-Gelbard, J Jiménez-Cauhé, D Saceda-Corralo, S Vaño-Galván
The objective of our study was to analyze the effectiveness of oral minoxidil on the frontotemporal hairline in patients with FFA. We conducted a retrospective, descriptive, multicenter study in 2 Brazilian and 1 Spanish centers. Responses were graded on a scale of 3 positive points. A total of 122 patients were included. Subjective improvement in the density of the frontotemporal hairline was observed in 45.1% patients, which was categorized as mild (34.4%), moderate (9.0%), and excellent (1.6%). Hair density improved in 57.4% of the patients' interparietal. Additionally, 25.4% and 3.3% of the patients experienced eyebrow and eyelash growth, respectively. Adverse effects were detected in 33.6% patients, with hypertrichosis being the most common (23.8%). In this study, oral minoxidil proved to be an additional therapy for FFA that not only improved the patients' overall hair and eyebrow growth, but also the density of the frontotemporal hairline.
{"title":"[Translated article] Low-dose Oral Minoxidil for Frontal Fibrosing Alopecia: A 122-patient Case Series.","authors":"C Pindado-Ortega, R Pirmez, D F Melo, L J F Binato, M L Porriño-Bustamante, J B Carpi, R Gil-Redondo, Á Hermosa-Gelbard, J Jiménez-Cauhé, D Saceda-Corralo, S Vaño-Galván","doi":"10.1016/j.ad.2025.02.008","DOIUrl":"10.1016/j.ad.2025.02.008","url":null,"abstract":"<p><p>The objective of our study was to analyze the effectiveness of oral minoxidil on the frontotemporal hairline in patients with FFA. We conducted a retrospective, descriptive, multicenter study in 2 Brazilian and 1 Spanish centers. Responses were graded on a scale of 3 positive points. A total of 122 patients were included. Subjective improvement in the density of the frontotemporal hairline was observed in 45.1% patients, which was categorized as mild (34.4%), moderate (9.0%), and excellent (1.6%). Hair density improved in 57.4% of the patients' interparietal. Additionally, 25.4% and 3.3% of the patients experienced eyebrow and eyelash growth, respectively. Adverse effects were detected in 33.6% patients, with hypertrichosis being the most common (23.8%). In this study, oral minoxidil proved to be an additional therapy for FFA that not only improved the patients' overall hair and eyebrow growth, but also the density of the frontotemporal hairline.</p>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ad.2024.05.021
J. Perales Pascual , H. Navarro Aznárez , A. López Pérez , T. Gracia-Cazaña , Y. Gilaberte Calzada , Mª R. Abad Sazatornil
Background
Patient-reported outcomes (PROs) are outcomes evaluated by patients based on their perception of their disease and treatment.
Objectives
Determine antipsoriatic treatment-related adherence, quality of life (QoL) and satisfaction.
Materials and Methods
We conducted an observational cross-sectional, prospective, and single-center study in which PROs surveys were conducted on adherence (Morisky-Green [MG] test), treatment satisfaction (Spanish Questionnaire of Treatment Satisfaction in Psoriasis [CESTEP]) and QoL (Skindex-29 and DLQI). Additional variables include: PASI, BSA. Statistical analysis: Jamovi®2.3.26.
Results
A total of 100 surveys were conducted. Based on the MG questionnaire, we found that 75% (75/100) of patients were adherent vs 94% (94/100) from the dispensation records. Regarding CESTEP, a mean score of 7.4 ± 7.7 (close to maximum satisfaction 0) was obtained, while DLQI yielded a score of 2.6 ± 4.6 (indicating a small effect on QoL), and SKINDEX-29 a score of 14.6 ± 15.4 (68% indicating mild (< 5) or very mild (6-17) impact according to Nijsten et al.).
Based on CESTEP a p.Rho Spearman value of 0.338 (p = 0.004) was obtained in relation to PASI when the study was conducted with a BSA of 0.255 (p = 0.050), DLQI results of 0.508 (p < 0.001) and Skindex-29 results of 0.397(p < 0.001). At the time of the study, the correlation matrix between DLQI result and PASI was 0.365 (p = 0.002) with a BSA of 0.347 (p = 0.007). Skindex-29 results with PASI were 0.380 (p = 0.001) and with BSA, 0.295 (p = 0.022).
Conclusions
Patients on therapy exhibit a good QoL, high adherence and satisfaction with their treatment. A significant correlation was seen among satisfaction, QoL, and PASI-BSA at the time of the study.
{"title":"Resultados comunicados por el paciente, adherencia y satisfacción en pacientes con psoriasis","authors":"J. Perales Pascual , H. Navarro Aznárez , A. López Pérez , T. Gracia-Cazaña , Y. Gilaberte Calzada , Mª R. Abad Sazatornil","doi":"10.1016/j.ad.2024.05.021","DOIUrl":"10.1016/j.ad.2024.05.021","url":null,"abstract":"<div><h3>Background</h3><div>Patient-reported outcomes (PROs) are outcomes evaluated by patients based on their perception of their disease and treatment.</div></div><div><h3>Objectives</h3><div>Determine antipsoriatic treatment-related adherence, quality of life (QoL) and satisfaction.</div></div><div><h3>Materials and Methods</h3><div>We conducted an observational cross-sectional, prospective, and single-center study in which PROs surveys were conducted on adherence (Morisky-Green [MG] test), treatment satisfaction (Spanish Questionnaire of Treatment Satisfaction in Psoriasis [CESTEP]) and QoL (Skindex-29 and DLQI). Additional variables include: PASI, BSA. Statistical analysis: Jamovi®2.3.26.</div></div><div><h3>Results</h3><div>A total of 100 surveys were conducted. Based on the MG questionnaire, we found that 75% (75/100) of patients were adherent vs 94% (94/100) from the dispensation records. Regarding CESTEP, a mean score of 7.4<!--> <!-->±<!--> <!-->7.7 (close to maximum satisfaction 0) was obtained, while DLQI yielded a score of 2.6<!--> <!-->±<!--> <!-->4.6 (indicating a small effect on QoL), and SKINDEX-29 a score of 14.6<!--> <!-->±<!--> <!-->15.4 (68% indicating mild (< 5) or very mild (6-17) impact according to Nijsten et al.).</div><div>Based on CESTEP a p.Rho Spearman value of 0.338 (p<!--> <!-->=<!--> <!-->0.004) was obtained in relation to PASI when the study was conducted with a BSA of 0.255 (p<!--> <!-->=<!--> <!-->0.050), DLQI results of 0.508 (p <<!--> <!-->0.001) and Skindex-29 results of 0.397(p <<!--> <!-->0.001). At the time of the study, the correlation matrix between DLQI result and PASI was 0.365 (p<!--> <!-->=<!--> <!-->0.002) with a BSA of 0.347 (p<!--> <!-->=<!--> <!-->0.007). Skindex-29 results with PASI were 0.380 (p<!--> <!-->=<!--> <!-->0.001) and with BSA, 0.295 (p<!--> <!-->=<!--> <!-->0.022).</div></div><div><h3>Conclusions</h3><div>Patients on therapy exhibit a good QoL, high adherence and satisfaction with their treatment. A significant correlation was seen among satisfaction, QoL, and PASI-BSA at the time of the study.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 2","pages":"Pages 141-146"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ad.2024.10.042
A. Martorell-Calatayud , S. Santos-Alarcón , A. Sahuquillo-Torralba , R. Rivera-Díaz , I. Belinchón-Romero , D. Ruiz-Genao , A. Romero-Maté , R. Ruiz-Villaverde , M. Ferran-Farrés , F. Gallardo-Hernández , M. Almenara-Blasco , J.A. Suarez-Perez , Á. González-Cantero , E. Martínez-Lorenzo , J.M. Fernández-Armenteros , E. del Alcázar-Viladomiu , J. García-Latasa , V. Rocamora-Durant , M. Ara-Martín , A. Mateu-Puchades , J. Magdaleno-Tapial
Background and objective
Risankizumab – a humanized monoclonal antibody that targets the p19 subunit of IL-23 – has been recently approved to treat moderate-to-severe plaque psoriasis. Real-world data based on a representative pool of patients are currently lacking.
Objective
To assess the mid- and long-term safety and efficacy profile of risankizumab in patients with moderate-to-severe psoriasis in the routine clinical practice.
Methods
This was a retrospective and multicenter study of consecutive psoriatic patients on risankizumab from April 2020 through November 2022. The primary endpoint was the number of patients who achieved a 100% improvement in their Psoriasis Area and Severity Index (PASI) (PASI100) on week 52.
Results
A total of 510 patients, 198 (38.8%) women and 312 (61.2%) men were included in the study. The mean age was 51.7 ± 14.4 years. A total of 227 (44.5%) study participants were obese (body mass index [BMI] >30 kg/m2). The mean baseline PASI score was 11.4 ± 7.2, and the rate of patients who achieved PASI100 on week 52, 67.0%. Throughout the study follow-up, 21%, 50.0%, 59.0%, and 66% of the patients achieved PASI100 on weeks 4, 16, 24, and 40, respectively. The number of patients who achieved a PASI ≤2 was greater in the group with a BMI ≤30 kg/m2 on weeks 4 (P = .04), 16 (P = .001), and 52 (P = .002). A statistically significantly greater number of patients achieved PASI100 in the treatment-naïve group on weeks 16 and 52 (P = .001 each, respectively). On week 16 a significantly lower number of participants achieved PASI100 in the group with psoriatic arthropathy (P = .04). Among the overall study sample, 22 (4.3%) patients reported some type of adverse event and 20 (3.9%) discontinued treatment.
Conclusions
Risankizumab proved to be a safe and effective therapy for patients with moderate-to-severe psoriasis in the routine clinical practice.
{"title":"[Artículo traducido] Eficacia y seguridad del risankizumab en pacientes con psoriasis en el mundo real: un estudio retrospectivo, multicéntrico y no intervencionista","authors":"A. Martorell-Calatayud , S. Santos-Alarcón , A. Sahuquillo-Torralba , R. Rivera-Díaz , I. Belinchón-Romero , D. Ruiz-Genao , A. Romero-Maté , R. Ruiz-Villaverde , M. Ferran-Farrés , F. Gallardo-Hernández , M. Almenara-Blasco , J.A. Suarez-Perez , Á. González-Cantero , E. Martínez-Lorenzo , J.M. Fernández-Armenteros , E. del Alcázar-Viladomiu , J. García-Latasa , V. Rocamora-Durant , M. Ara-Martín , A. Mateu-Puchades , J. Magdaleno-Tapial","doi":"10.1016/j.ad.2024.10.042","DOIUrl":"10.1016/j.ad.2024.10.042","url":null,"abstract":"<div><h3>Background and objective</h3><div>Risankizumab – a humanized monoclonal antibody that targets the p19 subunit of IL-23 – has been recently approved to treat moderate-to-severe plaque psoriasis. Real-world data based on a representative pool of patients are currently lacking.</div></div><div><h3>Objective</h3><div>To assess the mid- and long-term safety and efficacy profile of risankizumab in patients with moderate-to-severe psoriasis in the routine clinical practice.</div></div><div><h3>Methods</h3><div>This was a retrospective and multicenter study of consecutive psoriatic patients on risankizumab from April 2020 through November 2022. The primary endpoint was the number of patients who achieved a 100% improvement in their Psoriasis Area and Severity Index (PASI) (PASI100) on week 52.</div></div><div><h3>Results</h3><div>A total of 510 patients, 198 (38.8%) women and 312 (61.2%) men were included in the study. The mean age was 51.7<!--> <!-->±<!--> <!-->14.4 years. A total of 227 (44.5%) study participants were obese (body mass index [BMI] >30<!--> <!-->kg/m<sup>2</sup>). The mean baseline PASI score was 11.4<!--> <!-->±<!--> <!-->7.2, and the rate of patients who achieved PASI100 on week 52, 67.0%. Throughout the study follow-up, 21%, 50.0%, 59.0%, and 66% of the patients achieved PASI100 on weeks 4, 16, 24, and 40, respectively. The number of patients who achieved a PASI ≤2 was greater in the group with a BMI ≤30<!--> <!-->kg/m<sup>2</sup> on weeks 4 (<em>P</em> <!-->=<!--> <!-->.04), 16 (<em>P</em> <!-->=<!--> <!-->.001), and 52 (<em>P</em> <!-->=<!--> <!-->.002). A statistically significantly greater number of patients achieved PASI100 in the treatment-naïve group on weeks 16 and 52 (<em>P</em> <!-->=<!--> <!-->.001 each, respectively). On week 16 a significantly lower number of participants achieved PASI100 in the group with psoriatic arthropathy (<em>P</em> <!-->=<!--> <!-->.04). Among the overall study sample, 22 (4.3%) patients reported some type of adverse event and 20 (3.9%) discontinued treatment.</div></div><div><h3>Conclusions</h3><div>Risankizumab proved to be a safe and effective therapy for patients with moderate-to-severe psoriasis in the routine clinical practice.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 2","pages":"Pages T125-T133"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142492788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ad.2024.11.012
C.E. Morales-Múnera , F. Montoya , N. de Loredo , E. Sendagorta
Currently, ulcerative sexually transmitted infections, including syphilis, herpes simplex virus (HSV), lymphogranuloma venereum (LGV), chancroid, donovanosis and, more recently, monkeypox (MPOX), represent a growing challenge for health care professionals.
The incidence of syphilis and LGV has increased in recent years in Spain. Additionally, HSV, syphilis and chancroid can also increase the risk of HIV acquisition and transmission. The population groups most vulnerable to these infections are young people, men who have sex with men (MSM) and commercial sex workers.
It is important to make a timely differential diagnosis since genital, anal, perianal, and oral ulcerative lesions may pose differential diagnosis with other infectious and non-infectious conditions such as candidiasis vulvovaginitis, traumatic lesions, carcinoma, aphthous ulcers, Behçet's disease, fixed drug eruption, or psoriasis. For this reason, the dermatologist plays a crucial role in the diagnosis and management of sexually transmitted infections.
This chapter presents the main epidemiological, clinical and therapeutic features associated with these infections.
{"title":"[Translated article] AEDV Expert Document on the Management of Ulcerative Venereal Infections","authors":"C.E. Morales-Múnera , F. Montoya , N. de Loredo , E. Sendagorta","doi":"10.1016/j.ad.2024.11.012","DOIUrl":"10.1016/j.ad.2024.11.012","url":null,"abstract":"<div><div>Currently, ulcerative sexually transmitted infections, including syphilis, herpes simplex virus (HSV), lymphogranuloma venereum (LGV), chancroid, donovanosis and, more recently, monkeypox (MPOX), represent a growing challenge for health care professionals.</div><div>The incidence of syphilis and LGV has increased in recent years in Spain. Additionally, HSV, syphilis and chancroid can also increase the risk of HIV acquisition and transmission. The population groups most vulnerable to these infections are young people, men who have sex with men (MSM) and commercial sex workers.</div><div>It is important to make a timely differential diagnosis since genital, anal, perianal, and oral ulcerative lesions may pose differential diagnosis with other infectious and non-infectious conditions such as candidiasis vulvovaginitis, traumatic lesions, carcinoma, aphthous ulcers, Behçet's disease, fixed drug eruption, or psoriasis. For this reason, the dermatologist plays a crucial role in the diagnosis and management of sexually transmitted infections.</div><div>This chapter presents the main epidemiological, clinical and therapeutic features associated with these infections.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 2","pages":"Pages T159-T168"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142680526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ad.2024.05.003
L. Nina Dominguez , A. Imbernón-Moya , D. Saceda-Corralo , S. Vano-Galván
Trichotillomania (TTM) is an obsessive-compulsive disorder in which affected individuals recurrently pull-out hair from any region of the body, causing hair loss or alopecia. The management of TTM is a therapeutic challenge for dermatologists and consists of a combination of pharmacological and non-pharmacological alternatives. Cognitive-behavioral therapy has successfully been used to treat TTM. However, not all patients are willing to follow this treatment strategy. Unconventional support tools are proposed, such as electronic devices, internet therapies and microneedling. N-acetylcysteine and memantine are considered suitable first-line therapies thanks to their favorable safety and efficacy profile, low risk of adverse effects, and significant benefits. The use of other drugs, including fluoxetine, clomipramine, olanzapine, and naltrexone has limited evidence of variable efficacy. The present review illustrates the current treatment modalities for the management of TTM.
{"title":"Actualización en el tratamiento de la tricotilomanía","authors":"L. Nina Dominguez , A. Imbernón-Moya , D. Saceda-Corralo , S. Vano-Galván","doi":"10.1016/j.ad.2024.05.003","DOIUrl":"10.1016/j.ad.2024.05.003","url":null,"abstract":"<div><div>Trichotillomania (TTM) is an obsessive-compulsive disorder in which affected individuals recurrently pull-out hair from any region of the body, causing hair loss or alopecia. The management of TTM is a therapeutic challenge for dermatologists and consists of a combination of pharmacological and non-pharmacological alternatives. Cognitive-behavioral therapy has successfully been used to treat TTM. However, not all patients are willing to follow this treatment strategy. Unconventional support tools are proposed, such as electronic devices, internet therapies and microneedling. N-acetylcysteine and memantine are considered suitable first-line therapies thanks to their favorable safety and efficacy profile, low risk of adverse effects, and significant benefits. The use of other drugs, including fluoxetine, clomipramine, olanzapine, and naltrexone has limited evidence of variable efficacy. The present review illustrates the current treatment modalities for the management of TTM.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 2","pages":"Pages 152-158"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141069726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号